How Is Mineralys Therapeutics (NASDAQ:MLYS) Managing Market Adjustments and Institutional Transactions

2 min read | February 14, 2025 09:22 AM PST | By Team Kalkine Media

How Is Mineralys Therapeutics (NASDAQ:MLYS) Managing Market Adjustments and Institutional Transactions — Image source: shutterstock

Stock Market Adjustments and Trading Activity

Mineralys Therapeutics (NASDAQ:MLYS) has seen recent fluctuations in its stock performance, with its opening price at $10.15, down from its prior close of $10.63. The shift follows a revised outlook from The Goldman Sachs Group, adjusting its expectations from $28.00 to $24.00. Despite this adjustment, market engagement with the company remains active.

Executive Transactions and Insider Activity

Recent transactions among Mineralys Therapeutics executives include share sales by CEO Jon Congleton and CFO Adam Scott Levy. On January 13th, Congleton sold 18,333 shares at an average price of $9.06, reducing his holdings by 2.05% to 877,608 shares. CFO Adam Scott Levy also reduced his position, selling 10,757 shares at $9.10 each, lowering his stake by 4.54% to 226,097 shares. Insiders collectively hold 33.24% of the company’s stock.

Institutional Investment Developments

Institutional investors have made notable changes in their positions in Mineralys Therapeutics. Franklin Resources Inc. increased its holdings by 17.7% in the third quarter, now owning 1,745,513 shares valued at $21.14 million. The Vanguard Group Inc. raised its stake by 5.0%, reaching 1,432,042 shares valued at $17.63 million. Jennison Associates LLC expanded its position by 55.4% in the fourth quarter, bringing its total to 1,082,006 shares worth $13.32 million. Caligan Partners LP and ADAR1 Capital Management LLC also expanded their stakes, with institutional ownership now at 84.46%.

Financial Metrics and Business Direction

Mineralys Therapeutics holds a market capitalization of $507.65 million, with a reported negative PE ratio of -3.12. The company's moving averages are positioned at $11.21 for 50 days and $12.03 for 200 days. Recent earnings reports show a quarterly loss of ($0.98) per share, slightly ahead of projected figures.

Company Operations and Industry Role

Mineralys Therapeutics focuses on developing treatments for hypertension and chronic kidney diseases. Its flagship drug candidate, lorundrostat, is designed to target conditions associated with elevated aldosterone levels. As the company advances its clinical research, institutional participation and financial adjustments continue to shape its position within the biopharmaceutical sector.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.